The company is developing bone re-growth stimulation technologies and has an adaptive stem cell line called Marrow Isolated Adult Multi-Lineage Inducible cells. Vivex aims to introduce its stem cell and implant technologies to the market by early 2014.
More Articles on Devices:
Alphatec Holdings to Reduce Workforce, Operating Expenses for French Affiliate
Trinity Orthopedics Acquires Expanding Concepts’ Patent Portfolio
8 Key Notes on Spine & Orthopedic Medical Device Companies
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
